中基健康(000972) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue fell by 99.21% to ¥799,854.20, with a year-to-date revenue decline of 54.07% to ¥201,077,915.27[9] - Net profit attributable to shareholders was a loss of ¥5,350,650.69, with a year-to-date net profit of ¥22,860,511.96[9] - Basic and diluted earnings per share were both -¥0.007, compared to ¥0.0296 in the same period last year[9] - The net profit for the current period is CNY -5,426,876.19, an improvement compared to CNY -32,642,270.56 in the previous period[40] - The total comprehensive income for the current period is CNY -5,426,876.19, compared to CNY -30,441,238.79 in the previous period[41] - The company reported a significant increase in investment income of 2,145.16% to ¥6,826,084.05 from ¥304,036.20 due to gains from the disposal of subsidiary equity[16] - The company reported an investment income of CNY 6,826,084.05 for the current period, with no investment income reported in the previous period[39] Assets and Liabilities - Total assets decreased by 28.26% to ¥880,016,385.41 compared to the end of the previous year[9] - Current liabilities increased from CNY 400,321,585.69 to CNY 769,696,632.97, an increase of approximately 92.2%[31] - Total liabilities rose from CNY 414,445,456.83 to CNY 783,820,020.34, marking an increase of around 89%[31] - Owner's equity decreased from CNY 465,571,412.35 to CNY 442,872,397.02, a decline of about 4.9%[32] - The company has an accumulated deficit of CNY -1,493,317,330.47 in retained earnings[64] Cash Flow - Net cash flow from operating activities decreased by 68.50% to ¥54,803,106.71 year-to-date[9] - Cash received from the sale of goods and services dropped by 77.42% to ¥108,777,383.74 from ¥481,701,890.57, attributed to reduced sales volume[17] - Cash paid for purchasing goods and services decreased by 97.31% to ¥6,885,529.16 from ¥255,705,730.11, reflecting a reduction in procurement volume[17] - The cash inflow from operating activities for Q3 2019 was CNY 135,028,231.07, a decrease from CNY 536,427,055.17 in the previous year[53] - The net cash flow from operating activities for Q3 2019 was CNY 54,803,106.71, a decrease from CNY 173,961,072.91 in the previous period[54] - The company reported a net increase in cash and cash equivalents of CNY 3,059,277.51, contrasting with a decrease of CNY 88,794,846.77 in the previous period[55] Shareholder Information - The company had a total of 39,500 shareholders at the end of the reporting period[11] - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management, held 15.46% of shares[11] - No share repurchase transactions were conducted by the top 10 shareholders during the reporting period[13] Inventory and Receivables - Accounts receivable increased significantly by 464.68% to ¥53,050,579.00 from ¥9,394,830.00 as a result of sales of products[16] - Inventory decreased by 73.08% to ¥65,291,855.94 from ¥242,546,184.67 due to product sales[16] Compliance and Audit - There were no violations regarding external guarantees during the reporting period[24] - The company has not undergone an audit for the third quarter report[68] - The company has not disclosed any new product developments or market expansion strategies in this report[68]